Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New data on chemotherapy in the adjuvant setting.

M J Piccart1, C Sotiriou, F Cardoso

  • 1Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium. martine.piccart@bordet.be

Breast (Edinburgh, Scotland)
|December 9, 2003
PubMed
Summary

New breast cancer research explores molecular markers and gene expression profiles to predict chemotherapy benefit. A clinical trial suggests dose-dense chemotherapy may improve outcomes for node-positive breast cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.

Cancer treatment reviews·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Genotype imputation performance in Nellore cattle across different SNP panels and software tools.

Tropical animal health and production·2026
Same author

Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access.

Journal of medical economics·2026
Same author

Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

ESMO open·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Current adjuvant chemotherapy (CT) decisions for breast cancer rely on clinical-pathological criteria.
  • Emerging data suggest molecular markers and gene expression profiles may offer improved prognostic and predictive value.
  • The optimal scheduling of adjuvant CT, specifically dose-dense regimens, is under investigation.

Purpose of the Study:

  • To review recent provocative data with potential implications for future adjuvant chemotherapy prescription in breast cancer.
  • To assess the predictive value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) for CT benefit.
  • To explore the utility of gene expression profiles in predicting breast cancer outcomes and to evaluate dose-dense CT regimens.

Main Methods:

Related Experiment Videos

  • Review of recent studies on molecular markers (uPA/PAI-1) and gene expression profiling in breast cancer.
  • Analysis of data from the CALGB 9741 trial investigating dose-dense adjuvant chemotherapy schedules.
  • Evaluation of prognostic and predictive capabilities of novel biomarkers and treatment strategies.

Main Results:

  • uPA and PAI-1 show prognostic value in node-negative breast cancer and may predict enhanced benefit from CT, though with limitations.
  • Gene expression profiles appear superior to current criteria for predicting outcomes in early-stage breast cancer, independent of lymph node status.
  • The CALGB 9741 trial results strongly support the concept of dose-dense chemotherapy for improving tumor eradication in node-positive breast cancer.

Conclusions:

  • Molecular markers and gene expression profiles hold promise for refining adjuvant CT decision-making in breast cancer.
  • Dose-dense chemotherapy regimens warrant further investigation and potential adoption into routine patient care.
  • Continued research and independent validation are crucial for integrating these advancements into clinical practice.